At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
SUN13837 injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury
In Brief
A Phase 2 clinical trial evaluating SUN13837 injection and Placebo for Acute Spinal Cord Injury. Completed, enrolled 65 participants across 67 sites in 7 countries.
Detailed Summary
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, SUN13837 Injection, when compared with the placebo (inactive substance) in participants with acute spinal cord injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Spinal Cord Injury
CountriesCanada, Czechia, France, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartAug 2012
Primary CompletionSep 2014
TodayJul 2026
First PostedJan 2, 2012
Enrollment StartAug 8, 2012
Primary CompletionSep 21, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.5 years ago
Interventions
SUN13837 injectiondrug
SUN13837 injection, injection 1 x daily for 28 doses
Placebodrug
Matching placebo, volume equivalent to injection 1 x daily for 28 doses